We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

20 hedge funds and large institutions have $15.6M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

337% more capital invested

Capital invested by funds: $3.58M → $15.6M (+$12M)

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

82% more funds holding

Funds holding: 11 → 20 (+9)

15% less call options, than puts

Call options by funds: $8.1M | Put options by funds: $9.51M

Holders
20
Holders Change
+9
Holders Change %
+81.82%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
6
Reduced
1
Closed
3
Calls
$8.1M
Puts
$9.51M
Net Calls
-$1.41M
Net Calls Change
-$1.4M

Top Buyers

1
VCAM
Valentine Capital Asset Management
California
+$4.43M
2
Zurich Cantonal Bank
Zurich Cantonal Bank
Switzerland
+$2.72M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.37M
4
Verition Fund Management
Verition Fund Management
Connecticut
+$1.55M
5
AIG
American International Group
New York
+$1M

Top Sellers

1
PCM
Prelude Capital Management
New York
-$1.14M
2
GT
Glenmede Trust
Pennsylvania
-$89.9K
3
TCM
Tradewinds Capital Management
Washington
-$5K
4
PFG
Piershale Financial Group
Illinois
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
VCAM
1
Valentine Capital Asset Management
California
$4.17M +$4.43M +97,660 +1,449%
Zurich Cantonal Bank
2
Zurich Cantonal Bank
Switzerland
$2.4M +$2.72M +60,000 New
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$2.08M +$2.37M +52,138 New
LPL Financial
4
LPL Financial
California
$1.6M +$342K +7,524 +23%
Verition Fund Management
5
Verition Fund Management
Connecticut
$1.36M +$1.55M +34,116 New
Jane Street
6
Jane Street
New York
$921K +$769K +16,936 +276%
AIG
7
American International Group
New York
$883K +$1M +22,122 New
VKH
8
Virtu KCG Holdings
New York
$615K +$105K +2,312 +18%
HighTower Advisors
9
HighTower Advisors
Illinois
$471K +$536K +11,808 New
Millennium Management
10
Millennium Management
New York
$469K +$533K +11,740 New
U
11
UBS
Switzerland
$129K +$147K +3,230 New
Creative Planning
12
Creative Planning
Kansas
$98K +$69.9K +1,540 +167%
GT
13
Glenmede Trust
Pennsylvania
$91K -$89.9K -1,980 -46%
Bank of America
14
Bank of America
North Carolina
$76K +$86.7K +1,910 New
Citigroup
15
Citigroup
New York
$74K +$83.9K +1,848 New
CAL
16
Capital Analysts LLC
Pennsylvania
$69.1K +$78.5K +1,730 New
BCM
17
Blume Capital Management
California
$48K +$54.5K +1,200 New
Morgan Stanley
18
Morgan Stanley
New York
$27K +$9.08K +200 +42%
OIA
19
Optimum Investment Advisors
Illinois
$24K +$27.2K +600 New
S
20
SignatureFD
Georgia
$14K – – –
PCM
21
Prelude Capital Management
New York
– -$1.14M -30,248 Closed
TCM
22
Tradewinds Capital Management
Washington
– -$5K -120 Closed
PFG
23
Piershale Financial Group
Illinois
– -$3K -84 Closed

BIB Hedge Fund Activity: Q1 2014 in Review

20 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2014, worth a combined $15.6M — up 337% from $3.58M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new BIB positions and 3 closed out — a net gain of 9 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Valentine Capital Asset Management, adding an estimated $4.43M. The largest seller was Prelude Capital Management, exiting entirely with an estimated $1.14M sold.

  • 20 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2014, up from 11 in Q4 2013.
  • Funds reported $15.6M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2014, up 337% quarter-over-quarter.
  • 12 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2014 and 3 closed out, a net change of +9 holders.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2014 was Valentine Capital Asset Management, an estimated $4.43M added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2014 was Prelude Capital Management, an estimated $1.14M sold.

Based on aggregated 13F filings for Q1 2014.